Wawng Zhee

Role Summary:

Oversee overall strategy, business development, and day-to-day operations, spearheading company growth and expanding market presence.

Key Responsibilities:

• Lead global market research and deal execution, facilitating cross-border transactions for multinational corporations and Chinese enterprises.
• Establish and nurture strategic partnerships, strengthening relationships with key industry stakeholders and expanding the company’s client portfolio.

Key Achievements:

• Built and scaled the company’s operational infrastructure, successfully establishing a strong market footprint.
• Secured and executed high-impact consulting and market research projects for AstraZeneca, GenSci, and other leading multinational corporations.
• Facilitated high-profile cross-border transactions, enabling international expansion for CS Pharmaceuticals, Awafer, Hanvon, and Grahams Natural Alternatives.
• Generated close to RMB 1 million in revenue between May 2024 and March 2025, reflecting strong client engagement and commercial performance.

Role Summary:
Directed regional business strategy and market expansion, positioning KYBORA as a leading cross-border advisory firm in China and the broader APAC region.

Key Responsibilities:

• Led client acquisition and strategic partnerships, securing high-impact deals with Alebund, CS Pharmaceuticals, and China Resources.
• Oversaw asset licensing and M&A transactions, facilitating high-value cross-border investments.
• Supported fundraising efforts for KYBORA in China, helping establish strong investor relations and capital access for local operations.
• Established the company’s foundational presence in China, including bank account setup, office launch, local entity registration, partnership formation, and development of social media channels.

Key Achievements:

• Successfully anchored KYBORA’s China operations from the ground up, enabling seamless market entry and long-term scalability.
• Played a pivotal role in securing key local partnerships and building KYBORA’s brand visibility in the region.

Role Summary:
Served as the lead advisor for Chinese investors targeting opportunities in the global pharmaceutical and healthcare sectors, with a focus on strategic growth, compliance, and investment success.

Key Responsibilities:

• Conducted investment feasibility assessments and crafted market entry strategies for clients including BRL, Edding Pharma, HOPE Cell, SIRIO, MicroLife, and SDIC.
• Delivered expert guidance on regulatory compliance, portfolio diversification, and risk mitigation for international expansion.
• Built and led a consulting team from the ground up—recruiting 10 professionals including one dedicated business development specialist.
• Designed and delivered ongoing training programs to develop team capabilities in strategic advisory, client engagement, and market research.

Key Achievements:

• Successfully drove RMB 15 million in sales revenue in 2021 through high-impact advisory and deal execution.
• Developed a high-performing team culture that supported strong client satisfaction and repeat business.
• Despite a revenue shortfall in 2022 due to the COVID-related Shanghai lockdown, maintained client relationships and operational readiness for post-lockdown recovery.

• Led strategic consulting engagements, providing market intelligence and financial advisory to leading pharmaceutical companies.
• Cultivated and managed strong C-level relationships with clients such as Astellas, Sumitomo, MSD, and China Resources Lifesciences.
• Designed and executed business transformation initiatives to enhance financial outcomes and strengthen competitive advantage.

• Managed strategy consulting and market research projects with a focus on market expansion and investment advisory.
• Delivered financial modeling, competitive analysis, and risk assessment for clients including Xi’an Jessen, Bayer, Pfizer, Baxalta (formerly Baxter), Noxipoint, and Otsuka.

• Led global market research and investment feasibility studies for Fortune 500 healthcare and pharmaceutical companies.
• Conducted financial analysis, due diligence, and strategic planning, supporting multinational corporations in global investment strategies.